Is NCT06855706 recruiting in Buffalo, NY?

Yes, NCT06855706 is currently recruiting participants at its Buffalo, NY location. This endometrial carcinoma clinical trial is actively enrolling qualified participants.

How do I join the endometrial carcinoma clinical trial in Buffalo?

To join this clinical trial in Buffalo, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Buffalo clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Endometrial Carcinoma Clinical Trial in Buffalo, NY

About This Endometrial Carcinoma Study in Buffalo

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial cancer that is newly diagnosed. Physical activity is a modifiable risk factor for the prevention and treatment of many diseases. In fact, increased levels of physical activity have been shown to decrease the risk of some cancers as well as increase overall survival in some cancers. Currently, standard of care guidelines include participation in at least 150 minutes of moderate exercise weekly. An automated personalized physical activity intervention may increase physical activity, enhance quality of life, and improve physical function and daily living activities compared to standard recommendations in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer. This trial also evaluates the impact of physical activity on the gut microbiome and immune function. The microbiome is the collection of tiny organisms, like bacteria, that live in and on the body, especially places like the gut. These microorganisms play an important role in health. Information gathered from this study may help understand how the gut microbiome and physical activity influences the immune system in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer.

Sponsor: Roswell Park Cancer Institute

Who Can Participate

Inclusion Criteria

Age ≥ 18 years old on day of signing informed consent

Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Participant must satisfy one of the following conditions:

Have a clinically suspected or confirmed diagnosis of stage II-IV ovarian, primary peritoneal, or fallopian tube cancer by clinical presentation and elevated CA-125 and may be awaiting staging surgery or tumor tissue biopsy followed by neoadjuvant chemotherapy. Inclusion of clinically suspected ovarian cancer cases is because we want to capture data starting from the earliest point of the diagnostic pathway and before definitive staging surgery. This allows us to assess the impact of physical activity and the feasibility of wearable device monitoring as patients transition into neoadjuvant chemotherapy and potential surgery

Have recurrent ovarian, primary peritoneal, or fallopian tube cancer at any time point of their recurrence, if they meet eligibility criteria (any histology accepted). Inclusion of recurrent ovarian cancer cases is because ovarian cancer often recurs, and understanding physical activity patterns and interventions in patients experiencing recurrence is critical for comprehensive insights. This ensures the study includes the continuum of disease management beyond initial diagnosis

Have pre-operative biopsy-proven endometrial cancer (endometrioid, serous, mucinous, or clear cell, poorly differentiated) with plans for surgical resection using a minimally invasive approach or medical management with chemotherapy combination, hormonal treatment or radiation. Inclusion of biopsy-proven endometrial cancer cases but not clinically suspected or recurrent cases is because we are focusing on confirmed, newly diagnosed patients who will undergo surgical resection or medical management

willing to wear the activity tracking device for at least 70% of their waking hours each day (11 hours/day) throughout the 6-month study period

under the care of Roswell Park Comprehensive Cancer Center during the study period, which includes one or more of the following:

Receiving cancer treatment at Roswell Park Comprehensive Cancer Center

Undergoing surgery at Roswell Park Comprehensive Cancer Center

Participating in surveillance visits at Roswell Park Comprehensive Cancer Center

Receiving adjuvant treatment at an outside facility but returning to Roswell Park Comprehensive Cancer Center for periodic consultation visits and agreeing to comply with all study procedures, including data sharing from external providers

willing to participate in questionnaires and blood and stool collection throughout the study for translational research purposes

Participant must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure

Have a smartphone with daily internet access that is compatible with the wearable devices and applications used in the study (e.g., Fitbit Sense 2 and CGM applications)

NOTE: Patients who are already achieving or exceeding the goal of 150 minutes of physical activity per week are eligible for this study. This inclusion is intentional, as the study aims to evaluate the full spectrum of physical activity levels-both baseline activity and changes over time-and their relationship with clinical outcomes, metabolic measures (e.g., glucose levels), inflammation, and physical function

Exclusion Criteria

serious psychiatric illness that is not currently stabilized, including but not limited to:

Schizophrenia or other psychotic disorders

Bipolar disorder

Sever major depressive disorder

Severe personality disorders diagnosed by a qualified mental health professional

Recent suicide attempt or psychiatric hospitalization within the previous 12 months

Life expectancy of less than 12 months, as determined by the Investigator based on clinical judgment and available prognostic tools

history of other invasive malignancies within the last two years, except for:

Non-melanoma skin cancer

In situ cervical cancer

resting heart rate greater than 120 beats per minute after 10 minutes of seated rest, confirmed on two separate measurements

systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 100 mmHg, measured after 10 minutes of seated rest, confirmed on two separate measurements

Unstable angina or myocardial infarction within the past 3 months.

Unstable Angina: Chest pain at rest or chest pain of increasing frequency, severity, or duration that requires medical attention

Myocardial Infarction: Heart attack diagnosed by a medical professional

Pregnant or nursing participants will be excluded, as confirmed via urine test during screening procedures.

unwilling or unable to follow the protocol requirements, including but not limited to:

Cognitive impairment that affects the ability to provide informed consent or comply with study procedures

Language barriers without access to adequate translation services

Lack of access to necessary technology (e.g., smartphones compatible with study devices)

Other factors that would prevent adherence to study protocols

Any condition which, in the Investigator's opinion, makes the patient unsuitable for participation in the study or may interfere with the patient's ability to comply with the study requirements or the safety of the patient. Conditions may include, but are not limited to:

Severe pulmonary disease

Uncontrolled metabolic disorders

Other significant medical conditions that pose a risk during increased physical activity

Participants who do not provide a valid cell phone number or do not consent to receive SMS messages from Fitabase for motivational and compliance monitoring purposes will be excluded from the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Buffalo?

Yes, this clinical trial (NCT06855706) has an active research site in Buffalo, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Endometrial Carcinoma Treatment Options in Buffalo, NY

If you're searching for endometrial carcinoma treatment options in Buffalo, NY, this clinical trial (NCT06855706) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Buffalo research site is actively enrolling participants for this clinical trial. You'll receive care from experienced endometrial carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all endometrial carcinoma clinical trials near you to find additional studies recruiting in your area.

Endometrial Carcinoma Clinical Trial in Buffalo, NY

Expert Care in Buffalo

IRB Approved

No-Cost Care

Apply for This Buffalo Location

Why Participate?

Simple Process